GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Embecta Corp (NAS:EMBC) » Definitions » ROA %

Embecta (Embecta) ROA % : 6.61% (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Embecta ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Embecta's annualized Net Income for the quarter that ended in Dec. 2023 was $80 Mil. Embecta's average Total Assets over the quarter that ended in Dec. 2023 was $1,216 Mil. Therefore, Embecta's annualized ROA % for the quarter that ended in Dec. 2023 was 6.61%.

The historical rank and industry rank for Embecta's ROA % or its related term are showing as below:

EMBC' s ROA % Range Over the Past 10 Years
Min: 4.54   Med: 39.11   Max: 57.94
Current: 4.54

During the past 5 years, Embecta's highest ROA % was 57.94%. The lowest was 4.54%. And the median was 39.11%.

EMBC's ROA % is ranked better than
69.99% of 863 companies
in the Medical Devices & Instruments industry
Industry Median: -1.93 vs EMBC: 4.54

Embecta ROA % Historical Data

The historical data trend for Embecta's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Embecta ROA % Chart

Embecta Annual Data
Trend Sep19 Sep20 Sep21 Sep22 Sep23
ROA %
- 57.94 54.36 23.86 6.12

Embecta Quarterly Data
Sep19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.33 4.65 4.94 1.95 6.61

Competitive Comparison of Embecta's ROA %

For the Medical Instruments & Supplies subindustry, Embecta's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Embecta's ROA % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Embecta's ROA % distribution charts can be found below:

* The bar in red indicates where Embecta's ROA % falls into.



Embecta ROA % Calculation

Embecta's annualized ROA % for the fiscal year that ended in Sep. 2023 is calculated as:

ROA %=Net Income (A: Sep. 2023 )/( (Total Assets (A: Sep. 2022 )+Total Assets (A: Sep. 2023 ))/ count )
=70.4/( (1086.4+1214.4)/ 2 )
=70.4/1150.4
=6.12 %

Embecta's annualized ROA % for the quarter that ended in Dec. 2023 is calculated as:

ROA %=Net Income (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=80.4/( (1214.4+1217.8)/ 2 )
=80.4/1216.1
=6.61 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Dec. 2023) net income data. ROA % is displayed in the 30-year financial page.


Embecta  (NAS:EMBC) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=80.4/1216.1
=(Net Income / Revenue)*(Revenue / Total Assets)
=(80.4 / 1109.2)*(1109.2 / 1216.1)
=Net Margin %*Asset Turnover
=7.25 %*0.9121
=6.61 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Embecta ROA % Related Terms

Thank you for viewing the detailed overview of Embecta's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


Embecta (Embecta) Business Description

Traded in Other Exchanges
Address
300 Kimball Drive, Suite 300, Parsippany, NJ, USA, 07054
Embecta Corp is a medical technology company. The company develops innovative technology, services, and solutions that help advance both clinical therapy for patients and clinical processes for healthcare providers. Its products include BD Pyxis, PureWick, Phasix among others.
Executives
David F Melcher director 1650 TYSONS BOULEVARD, SUITE 1700, MCLEAN VA 22102
Devdatt Kurdikar officer: President and CEO ONE BECTON DRIVE, FRANKLIN LAKES NJ 07417
Jacob Elguicze officer: Chief Financial Officer ONE BECTON DRIVE, FRANKLIN LAKES NJ 07417
Jeffrey Z Mann officer: SVP, GC, Head Corp. Dev., Secy 150 CLOVE ROAD, 9TH FLOOR, LITTLE FALLS NJ 07424
Jean Casner officer: Chief Human Resources Officer 150 CLOVE ROAD, LITTLE FALLS NJ 07424
Karen Prange director 1108 S RIO VISTA BLVD, FORT LAUDERDALE FL 33316
Ajay Kumar officer: SVP and CHRO C/O EMBECTA CORP., ONE BECTON DRIVE, FRANKLIN LAKES NJ 07417
Shaun Curtis officer: SVP, Global Manuf./Sup. Chain C/O EMBECTA CORP., ONE BECTON DRIVE, FRANKLIN LAKES NJ 07417
David Albritton director ONE BECTON DRIVE, FRANKLIN LAKES NJ 07417-1880
Milton Mayo Morris director 2121 ALLEN PARKWAY, APT 4075, HOUSTON TX 77019
Brian Capone officer: VP, CAO & Corp. Controller 150 CLOVE ROAD, 9TH FLOOR, LITTLE FALLS NJ 07424
Carrie L Anderson director 3005 HIGHLAND PARKWAY, SUITE 200, DOWNERS GROVE IL 60515
Claire Pomeroy director BECTON, DICKINSON AND COMPANY, 1 BECTON DRIVE, FRANKLIN LAKES NJ 07417
Christopher R Reidy director ONE ADP BLVD, ROSELAND NJ 07068
Robert J. Hombach director C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015